Abstract
Vaccinations have been given to people for at least 100 years of which 80 years formulated in adjuvants. Currently, aluminium- containing formulas and the oil-based substance called MF59 are the two adjuvants licensed for clinical use. Despite the massive use of aluminium adjuvant, its mechanism of action has been only recently addressed. In this review, we will discuss both the cellular and molecular mode of action of aluminium-containing adjuvants.
Keywords: Adjuvant, aluminium hydroxide, dendritic cell, NLRP3, Syk, uric acid and dsDNA
Current Pharmaceutical Design
Title:The Mechanism of Adjuvanticity of Aluminium-Containing Formulas
Volume: 18 Issue: 16
Author(s): Kaat Fierens and Mirjam Kool
Affiliation:
Keywords: Adjuvant, aluminium hydroxide, dendritic cell, NLRP3, Syk, uric acid and dsDNA
Abstract: Vaccinations have been given to people for at least 100 years of which 80 years formulated in adjuvants. Currently, aluminium- containing formulas and the oil-based substance called MF59 are the two adjuvants licensed for clinical use. Despite the massive use of aluminium adjuvant, its mechanism of action has been only recently addressed. In this review, we will discuss both the cellular and molecular mode of action of aluminium-containing adjuvants.
Export Options
About this article
Cite this article as:
Fierens Kaat and Kool Mirjam, The Mechanism of Adjuvanticity of Aluminium-Containing Formulas, Current Pharmaceutical Design 2012; 18 (16) . https://dx.doi.org/10.2174/138161212800166004
DOI https://dx.doi.org/10.2174/138161212800166004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies Getting in Sync: A New Ready-to-use Biofield Resonance Device (Vita Chip) Reduces Chronic Pain and Increases Wellbeing
Neuroscience and Biomedical Engineering (Discontinued) Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Recent Patents on the Baculovirus Systems
Recent Patents on Biotechnology Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Lymphangiogenesis and Anti-Tumor Immune Responses
Current Molecular Medicine Fluorescence- and Spin-Labeled Carbonic Anhydrase Inhibitors
Current Pharmaceutical Design